Navigation Links
YM BioSciences appoints Dr. Nick Glover as President and Chief Operating Officer
Date:6/3/2010

MISSISSAUGA, ON, June 3 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), today announced the appointment of Dr. Nick Glover to the newly created position of President and Chief Operating Officer. Dr. Glover will provide broad leadership to the Company and have primary responsibility for its operations and infrastructure, in particular the development and commercialization of YM's pipeline.

"After the successful merger of Cytopia into YM and with the further support of our investors, we have built YM into a vibrant company with a portfolio of promising late-stage products matched by a strong balance sheet. Given the potential of this outstanding platform, the Board and I believe that this is a critical opportunity in YM's development to similarly strengthen the leadership of the Company," said David Allan, Chairman and CEO of YM BioSciences. "Nick's operational experience, skill-set and leadership style are an ideal fit with YM BioSciences. His experience running a public company, in particular one that conducted international clinical trials in similar cancer indications as nimotuzumab, is a perfect complement for this role. In addition to this expertise, his background in small molecule drug design and his doctoral degree in chemistry are an excellent match for our JAK inhibitor and VDA programs."

Dr. Glover was formerly the President and Chief Executive Officer at Viventia Biotech Inc., a biopharmaceutical company involved in the discovery and development of monoclonal antibody-based technologies for the treatment of cancer. While at Viventia, Dr. Glover led the strategic development of a novel monoclonal antibody discovery platform, advancing three clinical products including a Phase III antibody for the treatment of advanced head and neck
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
2. YM BioSciences raises US$3.2 million in support of JAK 1/2 program
3. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
4. YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
5. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
6. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
7. YM BioSciences announces presentations on global nimotuzumab trials at ASCO annual meeting
8. YM BioSciences third quarter 2010 operational and financial results
9. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
10. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
11. YM BioSciences announces controlled equity offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... Athena Signature Series: Turning Cancer ‘Off’ – ... a professor in the Regulatory Biology Laboratory at the Salk ... points to an “off switch” for drug resistance in cancer. ... local research is making a global impact in the fight ... join host Cheryl K. Goodman, CEO of Social Global Mobile ...
(Date:11/18/2014)... Brothers Josh and Bryce Benbasat (ages ... PAWSitively Curing Cancer, Inc . in recognition of National ... organization is dedicated to raising funds for pet cancer ... University of Florida College of Veterinary Medicine . ... as the recipient of this vital funding. It will ...
(Date:11/18/2014)... 18, 2014 PDL BioPharma, Inc. (PDL) (NASDAQ: ... with the acquisition of Durata Therapeutics, Inc. by Actavis, ... the termination of PDL,s credit agreement with Durata, which ... $40 million, accrued interest, and prepayment and change of ... structured financing transaction with Durata in which PDL agreed ...
(Date:11/18/2014)... , Nov. 18, 2014  Novira Therapeutics, Inc., a ... treatment of chronic hepatitis B virus (HBV) infection, today ... appointed to its Scientific Advisory Board (SAB).  ... SAB," said Christian S. Schade , Chief Executive ... development experience which will be invaluable to Novira as ...
Breaking Biology Technology:PAWSitively Curing Cancer, Inc. Launched By Two Children for National Pet Cancer Awareness Month 2PAWSitively Curing Cancer, Inc. Launched By Two Children for National Pet Cancer Awareness Month 3PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics 2Novira Therapeutics Announces Appointment of Brian F. Daniels, M.D., to its Scientific Advisory Board 2Novira Therapeutics Announces Appointment of Brian F. Daniels, M.D., to its Scientific Advisory Board 3
... AMLN ) will be presenting at the FBR ... 28, 2008 at 9:45 a.m. ET / 6:45,a.m. PT. ... Pharmaceuticals, will be providing a corporate overview., The ... a,recording will be made available following the event. The ...
... AstraZeneca (NYSE:,AZN) announced today that it supports ... the company,s latest step to provide the public,with ... Sponsored by Sens. Charles Grassley of Iowa ... a national registry of payments that,biopharmaceutical companies, device ...
... Biosciences,Corporation (Nasdaq: MATK ) announced that it intends ... 2008 on June 4, 2008, at approximately 4:00,p.m. Eastern ... Martek will,conduct a conference call to discuss the results ... interested parties may listen to the call,live via webcast ...
Cached Biology Technology:AstraZeneca Supports Transparency Legislation on Payments to Health Care Providers 2
(Date:11/15/2014)... , Nov. 13, 2014  While we may still be ... McCoy used in "Star Trek" to gain instant access to ... to work with smartphones and tablets for monitoring and measuring ... healthcare world. This may seem a tad Orwellian to some, ... adopt some of these technological opportunities into their healthcare regime. ...
(Date:11/7/2014)... conjunction with the Glendale and ... the Verdugos has announced the " GLENDALE - ... to keep the Verdugo Regional Crime Lab operational after its ... existence, the Lab has processed more than 400 DNA samples, ... "Because our number one priority is the wellbeing of ...
(Date:11/6/2014)... November 6, 2014 - Insilico Medicine, Inc, a ... and age related diseases announced a research collaboration ... cancer, Champions Oncology, Inc (OTC: CSBR). , "There ... personalized medicine, but Champions Oncology,s TumorGraft technology is ... the chemotherapy regimen experimentally generating vast amounts of ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... Scientists from the LSU Museum of Natural Science, or MNS, ... ornithological research programs in the world. This study the ... only shaken up the avian evolutionary tree, but completely redrawn ... heavily upon the LSU MNS, genetic resources collection, will be ...
... DCA groundbreaking new study finds that genes significantly affect ... reasons why people vote and participate in the political ... H. Fowler, Christopher T. Dawes (of UC San Diego) ... California), appears in the May issue of the ...
... together the latest science from research groups around Australia, ... agricultural sectors, with a focus on steps that can ... our climate. , Speaking to the Farm Writers Association ... CSIRO scientist Dr Mark Howden, said it was time ...
Cached Biology News:'Early bird' project really gets the worm 2Why do people vote? Genetic variation in political participation 2
Kit includes your choice of reagents for labeling 3 x 10 9 cells and EasySep magnet....
Plasmid expressing PLAP reporter gene....
Puromycin resistance gene (pac), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
...
Biology Products: